Retatrutide
investig.
What it isTriple GIP, GLP-1 and glucagon receptor agonist; obesity.
Why this oneAdding glucagon agonism raises energy expenditure as well as suppressing appetite, giving the largest weight loss yet reported.
What limits itGI intolerance and heart rate rise. Investigational; long-term safety unknown.
FDA-approved for
- obesity / type 2 diabetes (investigational)
Off-label
- obesity
- type 2 diabetes (phase 3)
FDA label
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Not stated on label | Adults | 2.5 mg (0.19 mL) SC once weekly, wk 1–4 | 10 mg (0.75 mL) SC once weekly from wk 13 | 10 mg once weekly |
Titration Increase every 4 weeks: 2.5 mg (wk 1–4) → 5 mg (wk 5–8) → 7.5 mg (wk 9–12) → 10 mg (wk 13+).
Renal Undefined
Hepatic Undefined
Dose given once weekly; label states no interval other than the 4-week titration steps.
Instructions
- Subcutaneous injection by pen, once weekly.
Pregnancy Undefined
Lactation Undefined
NO BOXED WARNINGS
Principal riskGI intolerance and heart rate rise
Classes and tags
Clinical profile
Mechanism of action: Retatrutide ballicule
